What Causes CMML? Did I Do Anything to Cause My CMML?
At a Glance
CMML usually develops when acquired genetic changes arise in a blood-forming stem cell during a person’s lifetime. Most cases have no single identifiable cause, and ordinary diet, stress, or everyday lifestyle choices did not cause the disease.
A diagnosis of chronic myelomonocytic leukemia (CMML) naturally leads to questions about how and why it happened. It is incredibly common to wonder if something you did—or didn’t do—caused your illness. The short and most important answer is no: you did not cause your CMML through your lifestyle choices, ordinary diet, or stress levels. CMML is a type of blood cancer that develops when a single blood-forming stem cell in the bone marrow acquires genetic changes (mutations) [1]. These mutations accumulate during a person’s lifetime, and in most cases, no single cause can be identified [2].
How CMML Develops in the Body
CMML is primarily driven by somatic mutations. A somatic mutation is a genetic change acquired during your life that is not present in the egg or sperm, meaning it is generally not passed down to your children [3][1].
As we age, it is normal for some blood stem cells to acquire mutations and begin producing a slightly larger share of our blood cells—a very common condition called clonal hematopoiesis [1][2]. In most people, this never causes a problem. However, in people with CMML, a single stem cell (a clone) acquires a specific combination of mutations that cause it to multiply abnormally [1][4]. Reported estimates vary by study population and testing method, but over 90% of people with CMML have detectable mutations in genes such as TET2, SRSF2, ASXL1, or genes in the RAS pathway [3][5].
These mutations change how the stem cell behaves, causing it to produce too many monocytes (a type of white blood cell) and often leading to poorly formed, dysfunctional blood cells [6][7]. However, because symptoms and blood counts can vary between patients, having “too many monocytes” does not necessarily mean every patient has a high total white-blood-cell count.
The mutations found on blood tests (like next-generation sequencing) usually help doctors classify your disease and estimate risk, but they do not automatically identify exactly why the disease began, nor are they automatically targets for treatment. Your hematology team will interpret them alongside your symptoms, blood counts, and other clinical findings.
Because CMML originates from genetic errors within your own cells, it is not contagious [1]. You cannot give it to someone else through ordinary contact, food, or household exposure, and you cannot catch it from another person.
Known and Suspected Risk Factors
While most people never learn one specific cause for their CMML, researchers have identified several risk factors associated with a higher likelihood of developing the disease:
- Age: Advancing age is the single most significant risk factor. CMML is overwhelmingly a disease of older adults, with the median age at diagnosis often reported around 75 years [8][9].
- Prior Cancer Treatments: Depending on the study, an estimated 9% to 11% of CMML cases are classified as therapy-related CMML. This means the disease developed years after a patient received chemotherapy or radiation therapy for an entirely different cancer [10][11]. The life-saving treatments used for the first cancer can damage the DNA of bone marrow cells, increasing the risk of blood cancers later on [12].
- Inflammation and Autoimmune Diseases: Observational studies have found that people with a history of chronic inflammatory or autoimmune disorders may have a higher risk of developing CMML [13][14]. However, this is an association, not proof that the inflammation directly caused the leukemia [13].
- Smoking: Smoking is associated with a modestly increased risk of CMML [13]. It is important to know that this association cannot identify the cause of an individual case. While stopping smoking remains highly worthwhile for your overall health, you should not assume personal blame for your CMML.
Having one of these risk factors does not mean you will inevitably get CMML, and having CMML does not necessarily mean it was triggered by any specific risk factor [13][11].
What This Means for Your Family
Because the mutations driving CMML are typically acquired during your lifetime, the disease itself is usually not passed down to your children [3]. However, there is an important distinction between inheriting CMML and inheriting a predisposition to blood cancers. Extremely rare inherited (germline) variants can predispose some families to myeloid neoplasms, including CMML [15]. A standard blood-based sequencing result alone cannot always prove whether a variant is somatic or inherited.
Routine family testing is not needed for most patients. However, you should mention it to your hematologist or ask about genetic counseling if you were diagnosed at an unusually young age, have multiple relatives with blood cancers or unexplained low blood counts, or have a personal history of multiple cancers.
If you are feeling guilty or searching your past for a reason this happened, please be gentle with yourself. There is no proven way to prevent most cases of CMML, and your focus now can safely shift from “why did this happen?” to “how do we best manage it?”
Common questions in this guide
What causes chronic myelomonocytic leukemia?
Did my diet, stress, or lifestyle cause CMML?
What factors are associated with a higher risk of CMML?
Can chemotherapy or radiation from an earlier cancer lead to CMML?
What do genetic mutations found in CMML mean?
Is CMML inherited or can I pass it to my children?
Is CMML contagious?
Related questions
Show more
Get notified when new evidence is published on chronic monocytic leukemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Age-related mutations and chronic myelomonocytic leukemia.
Mason CC, Khorashad JS, Tantravahi SK, et al.
Leukemia 2016; (30(4)):906-13 doi:10.1038/leu.2015.337.
PMID: 26648538 - 2
How I diagnose and treat chronic myelomonocytic leukemia.
Patnaik MM
Haematologica 2022; (107(7)):1503-1517 doi:10.3324/haematol.2021.279500.
PMID: 35236051 - 3
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM, Tefferi A
American journal of hematology 2022; (97(3)):352-372 doi:10.1002/ajh.26455.
PMID: 34985762 - 4
Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM, Patnaik MM
Current opinion in hematology 2020; (27(1)):2-10 doi:10.1097/MOH.0000000000000553.
PMID: 31688455 - 5
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.
Patnaik MM, Tefferi A
Blood cancer journal 2016; (6()):e393 doi:10.1038/bcj.2016.5.
PMID: 26849014 - 6
Tet2 restrains inflammatory gene expression in macrophages.
Cull AH, Snetsinger B, Buckstein R, et al.
Experimental hematology 2017; (55()):56-70.e13 doi:10.1016/j.exphem.2017.08.001.
PMID: 28826859 - 7
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Geissler K, Jäger E, Barna A, et al.
European journal of haematology 2022; (109(1)):50-57 doi:10.1111/ejh.13768.
PMID: 35299281 - 8
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis.
Vardell VA, Ose J, Rets AV, et al.
Clinical lymphoma, myeloma & leukemia 2024; (24(12)):843-851 doi:10.1016/j.clml.2024.07.013.
PMID: 39179449 - 9
Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
Guru Murthy GS, Dhakal I, Mehta P
Leukemia & lymphoma 2017; (58(7)):1648-1654 doi:10.1080/10428194.2016.1258700.
PMID: 27881041 - 10
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
Patnaik MM, Vallapureddy R, Yalniz FF, et al.
American journal of hematology 2018; (93(1)):65-73 doi:10.1002/ajh.24939.
PMID: 29023992 - 11
Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
Subari S, Patnaik M, Alfakara D, et al.
Clinical lymphoma, myeloma & leukemia 2015; (15(9)):546-9.
PMID: 26189785 - 12
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza-Huante E, et al.
Blood advances 2024; (8(11)):2695-2706 doi:10.1182/bloodadvances.2024012565.
PMID: 38513082 - 13
Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?
Elbæk MV, Sørensen AL, Hasselbalch HC
Leukemia & lymphoma 2016; (57(8)):1793-9 doi:10.3109/10428194.2016.1143938.
PMID: 26879691 - 14
The Role of Inflammation in CMML Pathobiology and Progression.
Neupane N, Padron E
Current hematologic malignancy reports 2025; (20(1)):14 doi:10.1007/s11899-025-00756-z.
PMID: 41062769 - 15
The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.
Gundabolu K, Dave BJ, Alvares CJ, et al.
Case reports in genetics 2022; (2022()):6977041 doi:10.1155/2022/6977041.
PMID: 35281324
This page is for informational purposes only and does not constitute medical advice about CMML. Your hematologist can help interpret your personal risk factors, genetic testing, treatment history, and family history.